Durvalumab outcomes for patients with PD-L1 positive and negative stage III unresectable non-small cell lung cancer treated at veterans health administration facilities

被引：0
|
作者：
Burton, Elizabeth M.
Moore, Amanda
Nooruddin, Zohra
Cotarla, Ion
Simmons, Daniel
Davis, Laura
Reveles, Kelly R.
Datta, Paromita
Souza, Gabriel Roman
Irabor, Omoruyi Credit
Franklin, Kathleen
Jones, Xavier
Frei, Christopher R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA
[3] Univ Texas Hlth San Antonio, San Antonio, TX USA
[4] AstraZeneca, Gaithersburg, MD USA
[5] Univ Texas Austin, San Antonio, TX USA
[6] South Texas Vet Hlth Care Syst, San Antonio, TX USA
[7] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18793
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Durvalumab treatment initiation delays in patients with unresectable stage III non-small cell lung cancer treated at Veterans Health Administration facilities.
    Datta, Paromita
    Moore, Amanda
    Frei, Christopher R.
    Reveles, Kelly R.
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew
    Mulrooney, Tiernan
    Alkadimi, Munaf
    Whitehead, Jennifer
    Franklin, Kathleen
    Reichelderfer, Renee
    Williams, Madison H.
    Williams, Ryan A.
    Smith, Sarah Allison
    Jones, Xavier
    Nooruddin, Zohra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Racial disparities in the clinical use of durvalumab for patients with stage III unresectable non-small cell lung cancer treated at Veterans Health Administration facilities.
    Moore, Amanda
    Nooruddin, Zohra
    Reveles, Kelly R.
    Datta, Paromita
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew
    Mulrooney, Tiernan
    Jones, Xavier
    Frei, Christopher R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration
    Moore, Amanda M.
    Nooruddin, Zohra
    Reveles, Kelly R.
    Koeller, Jim M.
    Whitehead, Jennifer M.
    Franklin, Kathleen
    Datta, Paromita
    Alkadimi, Munaf
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew J.
    Mulrooney, Tiernan
    Jones, Xavier
    Frei, Christopher R.
    ONCOLOGIST, 2023, 28 (09): : 804 - 811
  • [4] Treatment interruptions and discontinuations among patients with stage III unresectable non-small cell lung cancer treated with durvalumab at the Veterans Health Administration.
    Alkadimi, Munaf
    Moore, Amanda
    Frei, Christopher R.
    Reveles, Kelly R.
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew
    Mulrooney, Tiernan
    Datta, Paromita
    Whitehead, Jennifer
    Franklin, Kathleen
    Reichelderfer, Renee
    Williams, Madison H.
    Williams, Ryan A.
    Smith, Sarah Allison
    Jones, Xavier
    Nooruddin, Zohra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
    Vrankar, Martina
    Kern, Izidor
    Stanic, Karmen
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [6] Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
    Martina Vrankar
    Izidor Kern
    Karmen Stanic
    Radiation Oncology, 15
  • [7] Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab
    Nindra, Udit
    Shahnam, Adel
    Stevens, Samuel
    Pal, Abhijit
    Nagrial, Adnan
    Lee, Jenny
    Yip, Po Yee
    Adam, Tamiem
    Boyer, Michael
    Kao, Steven
    Bray, Victoria
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (01) : 16 - 24
  • [8] PD-L1 expression and survival in stage III unresectable non-small cell lung cancer patients in Denmark
    Cronin-Fenton, D.
    Dalvi, T.
    Movva, N.
    Pedersen, L.
    Hansen, H.
    Fryzek, J.
    Mellemgaard, A.
    Rasmussen, T.
    Klein, A. B.
    Hamilton-Dutoit, S.
    Norgaard, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S808 - S808
  • [9] Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
    Paz-Ares, L.
    Spira, A.
    Raben, D.
    Planchard, D.
    Cho, B. C.
    Ozguroglu, M.
    Daniel, D.
    Villegas, A.
    Vicente, D.
    Hui, R.
    Murakami, S.
    Spigel, D.
    Senan, S.
    Langer, C. J.
    Perez, B. A.
    Boothman, A-M
    Broadhurst, H.
    Wadsworth, C.
    Dennis, P. A.
    Antonia, S. J.
    Faivre-Finn, C.
    ANNALS OF ONCOLOGY, 2020, 31 (06) : 798 - 806
  • [10] PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
    Kaesmann, Lukas
    Nieto, Alexander
    Taugner, Julian
    Manapov, Farkhad
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (04) : 705 - 708
12345